SCHEMBL7674175

SCHEMBL7674175

Cc1ccc2c(c1C)N(CCCBr)c1ccccc1N(C)C2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.38
BCHE P06276 2/20 0.38
MAPT P10636 4/20 0.36
DRD2 P14416 2/20 0.36
HTR6 P50406 2/20 0.36
LMNA P02545 1/20 0.36
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR7 P34969 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
HDAC3 O15379 1/20 0.36
TUBB4A P04350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6745374 0.78 CES1 (0.35) CES1BCHEDRD3ALDH1A1ALDH2
SCHEMBL6744931 0.71 CYP2D6 (0.48) MAPTDRD2HTR6LMNACHRM2
SCHEMBL6744309 0.68 CES1 (0.34) CES1BCHEMAPTDRD2HTR6
SCHEMBL17298325 0.68 HTR2A (0.44) CES1BCHEMAPTDRD2HTR6
SCHEMBL6746810 0.67 TTR (0.41) CES1MAPTDRD2HTR6TTR
SCHEMBL17298327 0.66 PIM1 (0.46) CES1BCHEMAPTDRD2HTR6
SCHEMBL28591995 0.65 CES1 (0.81) CES1BCHEALDH1A1ALDH2ALDH3A1
SCHEMBL56978 0.65 GLS (0.62) MAPTCHRM2TDP1L3MBTL1MEN1
SCHEMBL29351736 0.65 GLS (0.62) MAPTCHRM2TDP1L3MBTL1MEN1
SCHEMBL6744307 0.65 BCHE (0.32) CES1BCHEMAPTDRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489336-B2 PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES EISAI CO., LTD. (JP) 2002-12-03 US disclosed
US-20020103189-A1 Nitrogen-containing tricyclic compounds and drugs containing the same EISAI CO., LTD. 2002-08-01 US disclosed
US-6333322-B1 FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY EISAI CO., LTD. (JP) 2001-12-25 US disclosed
EP-0889037-A1 NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME Eisai Co., Ltd. (JP) 1999-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103189-A1 Nitrogen-containing tricyclic compounds and drugs containing the same HRH2, HRH1, HRH4 CES1 501/4885BCHE 530/4885MAPT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.